News

Fabre-Kramer refiles Gepirone ER with the FDA for the treatment of Major Depressive Disorder
   
GlaxoSmithKline and Fabre-Kramer Pharmaceuticals Enter Global Agreement For New Treatment Of Major Depressive Disorder
   
Fabre-Kramer Announces Positive Phase III Results for Gepirone ER in Major Depression Program
   
Fabre-Kramer Re-Acquires Gepirone ER Rights From Organon
   
   

 

 
 
 
 
 
 
 
Fabre-Kramer Pharmaceuticals, Inc.• 5847 San Felipe, Suite 2000• Houston, TX 77057
(713) 975-6900 • Fax (713) 977-1574
Email contact: info@fabrekramer.com
© 2005 Fabre-Kramer Pharmaceuticals, Inc.